February 20, 2015 : Episode 1

Video

Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More

Related Videos
Thierry Facon, MD
Marshall Posner, MD
C. Ola Landgren, MD, PhD
David Samuel Dicapua Siegel, MD
Alfred L. Garfall, MD, MS
Coral Olazagasti, MD
Noa Biran, MD
Lova L. Sun, MD, MSCE
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Noa Biran, MD
Related Content
Jay M. Short, PhD, chairman, chief executive officer and co-founder of BioAtla
July 23rd 2024

FDA Grants Fast Track Designation to Ozuriftamab Vedotin in Recurrent/Metastatic HNSCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

C. Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center
July 19th 2024

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

C. Ola Landgren, MD, PhD, professor, medicine, chief, Division of Myeloma, Department of Medicine, director, Sylvester Myeloma Institute, co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
July 18th 2024

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment

Francisco Hernandez-Ilizaliturri, MD, of Roswell Park
July 17th 2024

Sequencing of Bispecific Antibodies vs CAR T-Cell Therapies is Dependent on Several Factors in DLBCL, Multiple Myeloma